Mumbai – August 25, 2025 — GSK India has entered the oncology space in the country with the launch of Jemperli (dostarlimab) and Zejula (niraparib), two innovative therapies for gynecological cancers. This move marks a significant milestone in addressing treatment gaps for endometrial and ovarian cancers, both of which are projected to rise sharply in India, with endometrial cancers expected to increase by 78% and ovarian cancers by 69% by 2045.
Science Significance
From a scientific perspective, these drugs represent important breakthroughs. Jemperli is the first PD-1 immunotherapy approved in India for the second-line treatment of dMMR/MSI-H advanced or recurrent endometrial cancer. Clinical data from the GARNET trial demonstrated a 45.5% objective response rate, with durable responses extending beyond 24 months, underscoring its potential as a transformative option in endometrial cancer management. Zejula, on the other hand, is the only PARP inhibitor approved in India for first-line monotherapy maintenance therapy in ovarian cancer regardless of biomarker status, making it a universal and highly accessible choice. Its once-daily oral dosing adds a layer of convenience, particularly important for long-term treatment.
Regulatory Significance
The regulatory significance of these approvals lies in the fact that they establish entirely new treatment categories in the Indian oncology landscape. Jemperli is the sole PD-1 immunotherapy available in its indication, while Zejula is the only PARP inhibitor that does not require biomarker stratification. Together, they represent an expansion of precision oncology access in India, a step that moves beyond traditional chemotherapy-based approaches and positions the country closer to international standards of cancer care.
Business Significance
Advertisement
From a business standpoint, these launches signify GSK India’s re-entry into oncology, with a deliberate focus on high-burden women’s cancers. The company has also adopted a tiered pricing framework, complemented by its Phoenix patient assistance program, which includes financial support mechanisms, aid for biomarker testing, and treatment counseling. These measures are designed to improve affordability and patient adherence, making these therapies more widely available.
Patients’ Significance
For patients, the availability of these therapies means meaningful alternatives to chemotherapy with the potential for improved survival outcomes and quality of life. Jemperli provides a durable immunotherapy option for difficult-to-treat endometrial cancer, while Zejula simplifies ovarian cancer maintenance treatment through its oral administration. With the addition of patient assistance programs, both financial and diagnostic barriers are expected to be reduced, thereby expanding the reach of these precision therapies.
Policy Significance
On a policy level, the introduction of Jemperli and Zejula aligns with India’s broader public health goals of expanding oncology treatment access. By addressing high-burden cancers and implementing affordability strategies, the move supports more equitable healthcare delivery. Furthermore, it reinforces the role of precision medicine in shaping the future of cancer care in India, ensuring that advanced therapies are no longer confined to select patient groups but are instead accessible to a wider population.
Transaction Highlights
In terms of transaction highlights, GSK India has successfully launched two oncology drugs that represent new therapeutic categories in the country. These approvals are backed by robust clinical evidence, including long-term durable responses. The combination of tiered pricing, patient support through the Phoenix program, and innovative precision therapy options underscores a shift toward accessible and effective cancer care. Ultimately, this entry into oncology reflects a strategic alignment of scientific advancement, regulatory progress, patient benefit, and health policy goals in India.
Source: GlaxoSmithKline Pharmaceuticals Ltd Press Release
